DaVita (DVA) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and DaVita published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. DaVita reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2026 GAAP results include a $62 million goodwill and other asset impairment charge related to DaVita's business in China. Adjusted EPS excludes it.
• DaVita's release compares most quarterly figures with the prior quarter, Q2 2026, and does not print a year-ago adjusted EPS for the quarter. Year-ago segment revenue here comes from the Q3 2026 10-Q.
• Revenue and net income are in millions to three decimals because DaVita reports its income statement in thousands.

Source: DaVita Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How DaVita splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• DaVita's U.S. dialysis revenue was $3.0 billion in Q3 2026, up 2% from $3.0 billion in Q3 2025, 85% of total revenue.
• DaVita's Other, ancillary services revenue was $552 million in Q3 2026, up 21% from $455 million in Q3 2025, 15% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

DaVita's release gives its current 2026 guidance as a table: adjusted operating income of $2,175 million to $2,250 million, adjusted diluted EPS of $14.30 to $15.20, and free cash flow of $1,000 million to $1,250 million.

In its Q3 2026 release, DaVita said:

“We do not provide guidance for operating income or diluted net income per share attributable to DaVita Inc. or operating cash flow on a basis consistent with United States generally accepted accounting principles (GAAP) nor a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts.”

“These current non-GAAP financial measures do not include certain items, including goodwill impairment charges and foreign currency fluctuations, which may be significant.”

Source: DaVita Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the DVA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP figures, each as first reported in that quarter's release. Q4 2025 diluted EPS of $3.29 is net income attributable to DaVita Inc.; diluted EPS from continuing operations was $2.94.

We do not hold a confirmed date for DaVita's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

DaVita's revenue is mostly dialysis. Of $3,578 million in total revenues in Q3 2026, dialysis patient service revenues were $3,408 million and other revenues $169.9 million. By segment, U.S. dialysis brought in $3,050 million and the ancillary services businesses (U.S. integrated kidney care, other U.S. ancillary services and international dialysis) $552 million, before $24 million of intersegment eliminations. (DaVita Q3 2026 release, Oct 29, 2026)

Medicare is DaVita's largest payor, and commercial insurers generally pay higher rates than Medicare. In Q3 2026 Medicare and Medicare Advantage accounted for $1,756.1 million of DaVita's dialysis patient service revenues and commercial payors $1,103.4 million. DaVita's 10-K says payments from commercial payors generate nearly all of its profits, and that about 26% of U.S. dialysis patient service revenues and about 11% of U.S. dialysis patients were tied to non-hospital commercial payors in 2025. (DaVita Form 10-Q, Q3 2026, Oct 29, 2026; DaVita Form 10-K, 2025, Feb 11, 2026)

DaVita performed 7,329,644 U.S. dialysis treatments in Q3 2026, an average of 92,780 a day, and normalized non-acquired treatment growth over Q3 2025 was 0.4%. Revenue per treatment was $415.25, against $415.87 in Q2 2026. DaVita put the quarter change down mainly to normal fluctuations, partly offset by higher average reimbursement rates and improvements in payor mix. (DaVita Q3 2026 release, Oct 29, 2026)

Within ancillary services, DaVita's U.S. integrated kidney care revenue was $144 million in Q3 2026, down from $162 million in Q2 2026, and international revenue was $398 million. At September 30, 2026 DaVita had about 80,800 patients in risk-based integrated care arrangements, representing about $6.4 billion of annualized medical spend, and its international business ran 598 outpatient dialysis centers in 14 countries. (DaVita Form 10-Q, Q3 2026, Oct 29, 2026; DaVita Q3 2026 release, Oct 29, 2026)

DaVita's GAAP diluted EPS was $3.40 in Q3 2026 and adjusted diluted EPS $3.82. The one adjustment was a non-cash goodwill and other asset impairment charge of $62 million related to DaVita's business in China, offset by a $1 million tax benefit and a $34 million noncontrolling interest credit, for a $27 million net income impact. The 10-Q says the charge resulted primarily from adverse reimbursement rate changes and related operating developments across non-renal hospital services. (DaVita Q3 2026 release, Oct 29, 2026; DaVita Form 10-Q, Q3 2026, Oct 29, 2026)

Buybacks have cut DaVita's share count: diluted shares were 65,504 thousand in Q3 2026, against 73,769 thousand a year earlier. DaVita repurchased 0.6 million shares for $111 million in the quarter, including 183 thousand shares bought from Berkshire Hathaway under their 2024 share repurchase agreement, and another 0.5 million shares for $87 million from October 1 to October 27, 2026. (DaVita Q3 2026 release, Oct 29, 2026; DaVita Form 10-Q, Q3 2026, Oct 29, 2026)

DaVita's effective income tax rate on income attributable to DaVita Inc. was 28.7% in Q3 2026, and 26.6% on adjusted income. Net income attributable to noncontrolling interests fell to $46.5 million from $89.9 million a year earlier. (DaVita Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

DaVita gives full-year guidance in its release for adjusted operating income, adjusted diluted EPS and free cash flow, and does not guide GAAP operating income or GAAP EPS. With Q3 2026 results it raised the bottom of two ranges: adjusted operating income to $2,175 million to $2,250 million, from $2,150 million to $2,250 million, and adjusted diluted EPS to $14.30 to $15.20, from $14.10 to $15.20. Free cash flow guidance stayed at $1,000 million to $1,250 million. (DaVita Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover DaVita, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones DaVita's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning DVA is on is DVA a buy or a sell?, what analysts expect next is on the DVA forecast, and what the company does is on the DaVita (DVA) stock page.

Every number on this page can be traced to a document DaVita published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.